STOCK TITAN

Immunovant Inc - IMVT STOCK NEWS

Welcome to our dedicated news page for Immunovant (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunovant's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunovant's position in the market.

Rhea-AI Summary
IMVT-1402 subcutaneous doses achieved peak IgG reductions similar to batoclimab. No decrease in serum albumin or increase in LDL-C observed. Encouraging pharmacodynamic data. MAD cohort showed 63% mean total IgG reduction with no adverse effects. 600 mg cohort dosing started. Conference call scheduled for discussing initial data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
97.04%
Tags
-
Rhea-AI Summary
Immunovant, Inc. will report initial IMVT-1402 Phase 1 results on September 26, 2023. Conference call and webcast to discuss the results will be held at 8:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
97.04%
Tags
conferences clinical trial
-
Rhea-AI Summary
Immunovant, Inc. reported corporate updates and financial results for its fiscal first quarter ended June 30, 2023. The Phase 1 clinical trial of IMVT-1402 is on schedule to deliver initial data in the coming months. The Phase 2 proof-of-concept data for batoclimab in Graves' disease is expected in Q4 2023. Global clinical trials of batoclimab are ongoing in myasthenia gravis, thyroid eye disease, and chronic inflammatory demyelinating polyneuropathy. Immunovant's cash and cash equivalents totaled $330.0 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.69%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.98%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.15%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.98%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.57%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
conferences
Immunovant Inc

Nasdaq:IMVT

IMVT Rankings

IMVT Stock Data

4.26B
64.36M
55.55%
47.61%
6.21%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
New York

About IMVT

immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.